AU2014346591B2 - Substituted N-acetyl-L-cysteine derivatives and related compounds - Google Patents

Substituted N-acetyl-L-cysteine derivatives and related compounds Download PDF

Info

Publication number
AU2014346591B2
AU2014346591B2 AU2014346591A AU2014346591A AU2014346591B2 AU 2014346591 B2 AU2014346591 B2 AU 2014346591B2 AU 2014346591 A AU2014346591 A AU 2014346591A AU 2014346591 A AU2014346591 A AU 2014346591A AU 2014346591 B2 AU2014346591 B2 AU 2014346591B2
Authority
AU
Australia
Prior art keywords
pro
pct
compound
rule
substitute sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014346591A
Other languages
English (en)
Other versions
AU2014346591A1 (en
Inventor
Daniel LAWTON
Michael NEARY
James Nieman
Garry Smith
Steven Tanis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promentis Pharmaceuticals Inc
Original Assignee
Promentis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promentis Pharmaceuticals Inc filed Critical Promentis Pharmaceuticals Inc
Publication of AU2014346591A1 publication Critical patent/AU2014346591A1/en
Application granted granted Critical
Publication of AU2014346591B2 publication Critical patent/AU2014346591B2/en
Priority to AU2018282446A priority Critical patent/AU2018282446B2/en
Priority to AU2020257084A priority patent/AU2020257084A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/26—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
    • C07C329/02—Monothiocarbonic acids; Derivatives thereof
    • C07C329/04—Esters of monothiocarbonic acids
    • C07C329/06—Esters of monothiocarbonic acids having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2014346591A 2013-11-08 2014-11-07 Substituted N-acetyl-L-cysteine derivatives and related compounds Ceased AU2014346591B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018282446A AU2018282446B2 (en) 2013-11-08 2018-12-21 Substituted N-acetyl-L-cysteine derivatives and related compounds
AU2020257084A AU2020257084A1 (en) 2013-11-08 2020-10-21 Substituted N-acetyl-L-cysteine derivatives and related compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361902052P 2013-11-08 2013-11-08
US61/902,052 2013-11-08
US201361902669P 2013-11-11 2013-11-11
US61/902,669 2013-11-11
PCT/US2014/064581 WO2015070034A1 (en) 2013-11-08 2014-11-07 Substituted n-acetyl-l-cysteine derivatives and related compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018282446A Division AU2018282446B2 (en) 2013-11-08 2018-12-21 Substituted N-acetyl-L-cysteine derivatives and related compounds

Publications (2)

Publication Number Publication Date
AU2014346591A1 AU2014346591A1 (en) 2016-05-26
AU2014346591B2 true AU2014346591B2 (en) 2018-09-27

Family

ID=51952031

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014346591A Ceased AU2014346591B2 (en) 2013-11-08 2014-11-07 Substituted N-acetyl-L-cysteine derivatives and related compounds
AU2018282446A Ceased AU2018282446B2 (en) 2013-11-08 2018-12-21 Substituted N-acetyl-L-cysteine derivatives and related compounds
AU2020257084A Abandoned AU2020257084A1 (en) 2013-11-08 2020-10-21 Substituted N-acetyl-L-cysteine derivatives and related compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018282446A Ceased AU2018282446B2 (en) 2013-11-08 2018-12-21 Substituted N-acetyl-L-cysteine derivatives and related compounds
AU2020257084A Abandoned AU2020257084A1 (en) 2013-11-08 2020-10-21 Substituted N-acetyl-L-cysteine derivatives and related compounds

Country Status (14)

Country Link
US (7) US9012674B1 (enExample)
EP (2) EP3674297A1 (enExample)
JP (4) JP6691044B2 (enExample)
AU (3) AU2014346591B2 (enExample)
CA (1) CA2929655C (enExample)
DK (1) DK3066089T3 (enExample)
ES (1) ES2765236T3 (enExample)
HU (1) HUE048345T2 (enExample)
LT (1) LT3066089T (enExample)
PL (1) PL3066089T3 (enExample)
PT (1) PT3066089T (enExample)
SI (1) SI3066089T1 (enExample)
WO (1) WO2015070034A1 (enExample)
ZA (1) ZA201705288B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112535A2 (en) * 2010-03-10 2011-09-15 Promentis Pharmaceuticals, Inc. Propionic acids, propionic acid esters, and related compounds
LT3066089T (lt) * 2013-11-08 2020-02-25 Promentis Pharmaceuticals, Inc. Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai
CN107735094B (zh) 2015-06-05 2021-05-28 中国医药大学 胱氨酸-谷氨酸转运蛋白的抑制剂的新用途
WO2018107040A1 (en) * 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated 1-(2-fluorophenyl)-n-[1-(2-fluoro-4-pyridyl)pyrazol-3-yl]cyclopropanecarboxamide, its solid forms and pharmaceutical uses thereof
UY37512A (es) * 2016-12-09 2019-04-30 Vertex Pharma Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga
US20190177295A1 (en) * 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Process for the preparation of a 1,3-disubstituted pyrazole compound
US20240425857A1 (en) 2021-10-29 2024-12-26 Vib Vzw Means and Methods for Chronic Wound Healing
CN116535998B (zh) * 2023-06-20 2024-05-17 安徽省阳明达新材料科技有限公司 一种热熔复合石材玻璃耐热eva胶片的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431186A (en) * 1965-02-25 1969-03-04 Hoechst Ag Electrolytic process for the cleavage of thiol esters of aromatic carboxylic acids
WO2000000469A2 (en) * 1998-06-29 2000-01-06 Parker Hughes Institute Alkyl ketones as potent anti-cancer agents
WO2009100431A1 (en) * 2008-02-07 2009-08-13 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
WO2013016727A1 (en) * 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1194117B (it) 1981-11-20 1988-09-14 Isnardi Pietro & C Spa Derivati salicilici di n-acetilcisteina
CN85107378A (zh) 1984-09-13 1987-03-18 陶氏化学公司 从原煤中回收有用煤的起泡剂组合物和泡沫浮选方法
US5637616A (en) 1993-06-18 1997-06-10 Arcturus Pharmaceutical Corporation Method for treating diseases mediated by proteases
AU1447095A (en) 1993-12-30 1995-07-17 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
WO1995034303A1 (en) 1994-06-13 1995-12-21 Arcturus Pharmaceutical Corporation Method for the treatment, prevention or minimization of hair loss
JP3608021B2 (ja) * 1996-09-05 2005-01-05 参天製薬株式会社 新規含硫黄アミノ酸誘導体
KR19990078146A (ko) 1998-03-24 1999-10-25 마키노 아라타 프로필렌계 수지 조성물 및 이를 사용한 연신필름
WO2001007400A1 (en) * 1999-07-26 2001-02-01 Toray Industries, Inc. Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient
JP4684553B2 (ja) 2001-09-27 2011-05-18 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 生理学的過程の調節およびこれに有用な薬剤
JP2005521645A (ja) 2001-12-04 2005-07-21 ベン グリオン ユニバーシティ オブ ザ ネジェブ リサーチ アンド ディベラップメント オーソリティ 器官特異的薬物ターゲティング用両親媒性化合物及び小胞／リポソーム
CN1233629C (zh) 2002-11-22 2005-12-28 贵州省中国科学院天然产物化学重点实验室 具有神经营养作用的硫酯类化合物及其它的合成方法和应用
FR2856592B1 (fr) 2003-06-27 2008-04-25 Oreal Composition cosmetique a base de percuseur(s) de radical thiyl pour la deformation permanente des fibres keratiniques
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
KR20080028357A (ko) 2005-04-21 2008-03-31 글렌 에이. 골드스타인 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드)
CA2620899A1 (en) 2005-10-12 2007-04-19 Biolipox Ab Benzoxazoles useful in the treatment of inflammation
JP2010505844A (ja) * 2006-10-03 2010-02-25 ガレオン・フアーマシユーチカルズ・インコーポレーテツド Ｓ−ニトロソチオール化合物および関連誘導体
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
EP2265594A2 (en) 2008-04-16 2010-12-29 Marquette University Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
CN102316730A (zh) 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
US8575217B2 (en) 2009-03-16 2013-11-05 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CA2787784A1 (en) 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
WO2011112535A2 (en) 2010-03-10 2011-09-15 Promentis Pharmaceuticals, Inc. Propionic acids, propionic acid esters, and related compounds
EP2614821B1 (en) 2010-09-06 2016-11-09 SNU R & DB Foundation Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof
JP2014502958A (ja) * 2010-11-12 2014-02-06 プロメンテイス・フアーマシユーテイカルズ・インコーポレイテツド Ｓ−ｔ−ブチル保護システインジペプチド類似体および関連化合物
US20120122793A1 (en) 2010-11-12 2012-05-17 Promentis Pharmaceuticals, Inc. S-Protected Cysteine Analogs and Related Compounds
IN2013MN01582A (enExample) 2011-01-20 2015-06-12 Oneday Biotech And Pharma Ltd
WO2014209412A1 (en) 2013-06-29 2014-12-31 Viva Pharmaceutical, Inc. N-acetyl l-cysteine chelates and methods for making and using the same
EP3019164B1 (en) 2013-07-10 2020-08-19 Glenn A. Goldstein Use of n-acetylcysteine amide in the treatment of penetrating head injury
WO2015057791A2 (en) 2013-10-15 2015-04-23 Goldstein Glenn A Use of n-acetylcysteine amide for decreasing intracranial pressure
LT3066089T (lt) * 2013-11-08 2020-02-25 Promentis Pharmaceuticals, Inc. Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai
US20150209309A1 (en) 2014-01-24 2015-07-30 Brighton Biotech, Inc Naca for the treatment of chronic or acute cognitive dysfunction
WO2015112715A1 (en) 2014-01-24 2015-07-30 Brighton Biotech, Inc. Naca for the treatment of chronic or low impact brian trauma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431186A (en) * 1965-02-25 1969-03-04 Hoechst Ag Electrolytic process for the cleavage of thiol esters of aromatic carboxylic acids
WO2000000469A2 (en) * 1998-06-29 2000-01-06 Parker Hughes Institute Alkyl ketones as potent anti-cancer agents
WO2009100431A1 (en) * 2008-02-07 2009-08-13 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
WO2013016727A1 (en) * 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs

Also Published As

Publication number Publication date
US10961187B2 (en) 2021-03-30
PT3066089T (pt) 2020-01-29
CA2929655C (en) 2023-06-13
CA2929655A1 (en) 2015-05-14
US20170210716A1 (en) 2017-07-27
JP7170811B2 (ja) 2022-11-14
US9630937B2 (en) 2017-04-25
US20190315683A1 (en) 2019-10-17
SI3066089T1 (sl) 2020-03-31
AU2020257084A1 (en) 2020-11-19
JP2020121993A (ja) 2020-08-13
LT3066089T (lt) 2020-02-25
WO2015070034A1 (en) 2015-05-14
JP2022003063A (ja) 2022-01-11
US9012674B1 (en) 2015-04-21
US10112897B2 (en) 2018-10-30
EP3066089A1 (en) 2016-09-14
US10358414B2 (en) 2019-07-23
EP3674297A1 (en) 2020-07-01
US20150133544A1 (en) 2015-05-14
AU2014346591A1 (en) 2016-05-26
PL3066089T3 (pl) 2020-04-30
US20210395194A1 (en) 2021-12-23
AU2018282446B2 (en) 2020-07-23
ZA201705288B (en) 2019-02-27
JP2018080164A (ja) 2018-05-24
JP6691044B2 (ja) 2020-04-28
HUE048345T2 (hu) 2020-07-28
JP6559756B2 (ja) 2019-08-14
JP2016537338A (ja) 2016-12-01
AU2018282446A1 (en) 2019-01-17
JP6952825B2 (ja) 2021-10-27
US20150133470A1 (en) 2015-05-14
ES2765236T3 (es) 2020-06-08
US20170183303A1 (en) 2017-06-29
EP3066089B1 (en) 2019-11-06
DK3066089T3 (da) 2020-01-27
US20240059649A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
US20240059649A1 (en) Substituted n-acetyl-l-cysteine derivatives and related compounds
CA2787785C (en) Compositions and methods for enhancing proteasome activity
TW202322806A (zh) 作為ｇｌｐ—１ｒ促效劑的化合物
JP2016510317A (ja) 重水素置換されたフマル酸誘導体
US20230024914A1 (en) Methods of treating respiratory disorders
WO2020051058A1 (en) 2,6-diamino pyridine compounds
US9193681B1 (en) Propionic acids, propionic acid esters, and related compounds
EA018024B1 (ru) Фенантреноновые соединения, композиции и способы
RU2386627C2 (ru) Селективные ингибиторы бутирилхолинэстеразы
TWI668007B (zh) 用於預防及治療神經退化疾病及疼痛之化合物
CN110183348A (zh) N-(3-硝基-4-烷氧基苯甲酰基)氨基酸类化合物、制备方法及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired